Synlogic logo
Synlogic SYBX

Annual report 2025
added 03-12-2026

report update icon

Synlogic Income Statement 2011-2026 | SYBX

Annual Income Statement Synlogic

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 16 M 11.6 M 2.82 M 110 M 135 M 86.6 M 180 M 65.4 M 44.2 M 93.9 M - - - -

Shares

12.3 M 12.2 M 6.5 M 4.78 M 55.3 M 36.3 M 30.3 M 23.9 M 6.72 M 2.98 M 2.98 M - - - -

Historical Prices

- 1.31 1.78 0.59 1.98 3.79 2.06 8.69 10.7 16.2 30.4 - - - -

Net Income

-1 M -23.4 M -61.3 M -66.1 M -60.6 M -59.2 M -51.4 M -48.4 M -40.4 M -26.3 M -25 M -15.8 M -6.44 M -3.66 M -

Revenue

- 8 K 3.37 M 1.18 M 1.75 M 545 K 2.22 M 2.52 M 2.44 M - - - - - -

Gross Profit

- - - - - 545 - - - - - - - - -

Operating Income

-4.01 M -41 M -55.2 M -67.4 M -60.8 M -60.5 M -54.4 M -51.2 M -40.8 M -21 M - - - - -

Interest Expense

- -2 K -914 K 2 K 2 K 6 K 21 K 43 K 57 K 7 K - - - - -

EBITDA

- -40.6 M -53.2 M -64.9 M -58.3 M -57.8 M -50.3 M -48.8 M -38.5 M -21.9 M -25 M -13.9 M -6.74 M -4.27 M -

Operating Expenses

4.01 M 41 M 58.5 M 68.6 M 62.5 M 61 M 56.6 M 53.8 M 43.3 M 22 M 25 M - - - -

General and Administrative Expenses

3.49 M 6.63 M 14.6 M 16.6 M 15.4 M 13.5 M 14.7 M 15.7 M 12.9 M 8.12 M 6.08 M 3.37 M 2.38 M 1.56 M -

All numbers in USD currency

Quarterly Income Statement Synlogic

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

12.3 M 12.3 M 12.3 M 11.7 M 12.2 M 12.2 M 12.1 M 9.19 M 4.7 M 4.68 M 4.6 M 4.45 M 4.81 M 72.1 M 72 M 69.7 M 55.3 M 52 M 41.5 M 38.2 M 36.3 M 35 M 34.2 M 32.3 M 34.2 M 27.2 M 25.3 M 25.4 M 25.2 M 24.8 M 20.1 M 16.3 M 7.17 M 2 M 20.9 M - 20.8 M 20.8 M 20.8 M 20.8 M 94.8 K 91.6 K 88.5 K 83.3 K 83.2 K - - - - - - - - - - - - - -

Net Income

-2.3 M -529 K 317 K - -117 K 3.08 M -25.6 M - -12.1 M -15 M -15.6 M - -17.9 M -15.8 M -15.7 M - -16 M -14.5 M -15 M -14.6 M -13.2 M -15.5 M -15.8 M -12.8 M -13.3 M -12.3 M -12.9 M -11.9 M -10.7 M -14.6 M -11.2 M -11.7 M -11.9 M -9.39 M -7.37 M -6.85 M -5.31 M -4.97 M -3.83 M -8.79 M -6.23 M -5.68 M -4.28 M -4.38 M -5.42 M -3 M -3.04 M - - - - - - - - - - - -

Revenue

- - - - - - 8 K - 393 K 35 K 174 K - 678 K 152 K 244 K - 916 K 246 K - - 545 K 445 K 100 K 1.23 M 305 K 350 K 338 K 111 K 1.8 M 254 K 354 K 111 K 111 K 2.11 M 111 K 111 K 111 K 111 K 111 K - - - - - - - - - - - - - - - - - - - -

Operating Income

-991 K -777 K -898 K - -748 K 419 K -38.8 M - -12.6 M -15.7 M -16.2 M - -18.3 M -16 M -15.8 M - -16.1 M -14.5 M -15 M -14.7 M -13.4 M -15.9 M -16.4 M -13.5 M -14.1 M -13.1 M -13.7 M -12.7 M -11.5 M -15.4 M -11.6 M -11.9 M -12.1 M -9.46 M -7.37 M -6.86 M -5.31 M -4.97 M -3.83 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - 1 K - -2 K - -1 K - 1 K - 1 K 1 K 1 K - 1 K 1 K - - 1 K 2 K 3 K - 5 K 5 K 7 K - 10 K 12 K 14 K - 7 K 7 K 8 K - 1 K - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - -38.5 M - - - -15.7 M - -16.4 M -14.8 M -15.2 M - -14.2 M -13.3 M -14.4 M -14.7 M -11.5 M -14.6 M -15.7 M -13.5 M -12.1 M -11.7 M -13 M -12.7 M -9.74 M -14.2 M -11 M -11.9 M -10.8 M -9.44 M -7.37 M -6.86 M -5.25 M -4.94 M -3.81 M - 12 K 13 K 12 K - 9 K - - - - - - - - - - - - - -

Operating Expenses

991 K 777 K 898 K - 748 K -419 K 38.9 M - 13 M 15.7 M 16.4 M - 19 M 16.2 M 16 M - 17 M 14.8 M 15 M 14.7 M 13.4 M 16.4 M 16.5 M 14.7 M 14.4 M 13.4 M 14 M 12.8 M 13.3 M 15.6 M 12 M 12 M 12.2 M 11.6 M 7.48 M 6.97 M 5.42 M 5.08 M 3.94 M 8.82 M 6.24 M 5.68 M 4.28 M 4.38 M 5.42 M 3 M 3.04 M - - - - - - - - - - - -

General and Administrative Expenses

818 K 800 K 836 K - 1.16 M 1.18 M 2.88 M - 3.4 M 3.92 M 3.97 M - 4.4 M 4.11 M 4.27 M - 3.62 M 4.06 M 3.85 M - 2.96 M 3.47 M 3.82 M - 3.88 M 3.74 M 3.65 M - 3.4 M 4.73 M 3.63 M - 3.23 M 3.04 M 2.37 M 2 M 1.29 M 2.05 M 2.13 M 2.46 M 1.56 M 1.18 M 877 K 877 K 715 K 929 K 848 K - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Synlogic (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 30.34 -0.82 % $ 286 B franceFrance
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.4 -0.71 % $ 360 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.5 3.83 % $ 27.2 B germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 -0.34 % $ 6.35 B israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.55 -0.78 % $ 16 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.37 -2.4 % $ 952 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 -2.16 % $ 436 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.21 -1.47 % $ 3.08 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.24 -4.1 % $ 2.14 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.13 -1.26 % $ 315 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.0 -2.91 % $ 152 M germanyGermany
Immutep Limited Immutep Limited
IMMP
$ 0.31 -2.52 % $ 1.08 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.83 -2.3 % $ 258 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA